Otsuka bids for a seat at the conjugate table
The acquisition of Araris follows a 2023 discovery collaboration.
Ono takes on Takeda in polycythemia vera
The Japanese group licenses sapablursen from Ionis for $280m.
ALX plays the conjugate card
Could a new ADC project distract attention away from evorpacept?
Merck and Sanofi sound the alarm for ILT inhibition
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
Chimerix turns $39m into $935m
The quiet acquisition of dordaviprone prompts a louder takeout by Jazz.
